Companies › Miltenyi Biomedicine
4 active drug programs in 12 registered trials: 8 Phase 1, 4 Phase 2; Oncology, Immunology, Neurology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| zamtocabtagene autoleucel (MB-CART2019.1) CD19-directed CAR-T cell therapy | CD19 | Phase 2 | Refractory Diffuse Large B Cell Lymphoma (DLBCL); DLBCL - Diffuse Large B Cell Lymphoma; B-Cell Neoplasm; Diffuse Large B-cell Lymphoma … | Dec 2026 |
| MB-CART19.1 Anti-CD19 CAR T cell therapy | CD19 | Phase 1 | Acute Lymphoblastic Leukemia Recurrent; SLE - Systemic Lupus Erythematosus | Nov 2026 |
| MB-dNPM1-TCR.1 T cell receptor (TCR) therapy targeting dNPM1 peptide epitopes restricted to HLA A*02:01 | NPM1 | Phase 1 | Leukemia, Myeloid, Acute | Jun 2028 |
| anti-CD19 CAR T cell therapy anti-CD19 CAR-T cell therapy | CD19 | Phase 1 | Systemic Lupus Erythematosus; Relapse/Refractory B-cell Acute Lymphoblastic Leukemia; Systemic Lupus Erthematosus | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06347718 | anti-CD19 CAR T cell therapy | Phase 1 | Systemic Lupus Erythematosus | Immunology | May 2026 |
| NCT03853616 | MB-CART19.1 | Phase 1 | Acute Lymphoblastic Leukemia Recurrent | Oncology | Nov 2026 |
| NCT04792489 | zamtocabtagene autoleucel (MB-CART2019.1) | Phase 2 | Refractory Diffuse Large B Cell Lymphoma (DLBCL) | Oncology | Dec 2026 |
| NCT07288879 | zamtocabtagene autoleucel (MB-CART2019.1) | Phase 2 | DLBCL - Diffuse Large B Cell Lymphoma | Oncology | Jan 2027 |
| NCT06635330 | anti-CD19 CAR T cell therapy | Phase 1 | Relapse/Refractory B-cell Acute Lymphoblastic Leukemia | Oncology | Sep 2027 |
| NCT06189157 | MB-CART19.1 | Phase 1 | SLE - Systemic Lupus Erythematosus | Immunology | Sep 2027 |
| NCT06828042 | anti-CD19 CAR T cell therapy | Phase 1 | Systemic Lupus Erthematosus | Immunology | Dec 2027 |
| NCT06708845 | zamtocabtagene autoleucel (MB-CART2019.1) | Phase 1 | Lupus Nephritis | Immunology | Jan 2028 |
| NCT06424340 | MB-dNPM1-TCR.1 | Phase 1 | Leukemia, Myeloid, Acute | Oncology | Jun 2028 |
| NCT06508931 | zamtocabtagene autoleucel (MB-CART2019.1) | Phase 2 | B-Cell Neoplasm | Oncology | Dec 2029 |
| NCT07178431 | zamtocabtagene autoleucel (MB-CART2019.1) | Phase 1 | Multiple Sclerosis | Neurology | Aug 2030 |
| NCT04844866 | zamtocabtagene autoleucel (MB-CART2019.1) | Phase 2 | Diffuse Large B-cell Lymphoma | Oncology | Sep 2031 |
Grit Biotechnology Fate Therapeutics Shanghai Ming Ju Biotechnology PersonGen BioTherapeutics (Suzhou) Beijing Yongtai Ruike Biotechnology Company
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.